Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY, USA.
Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY, USA.
J Hepatol. 2014 Nov;61(1 Suppl):S91-7. doi: 10.1016/j.jhep.2014.09.006. Epub 2014 Nov 3.
The treatment of hepatitis C virus (HCV) has made significant advances with the development of new direct-acting antivirals. Nucleotide polymerase inhibitors are one class of these new medications that have been shown to be highly effective, safe and well tolerated as part of an antiviral regimen. Sofosbuvir has become the first drug in this class to be approved for clinical use, supported by results from extensive phase II and phase III clinical trials. This review will further discuss nucleotide polymerase inhibitors, including the data supporting their use as part of interferon-free HCV treatment regimens.
丙型肝炎病毒 (HCV) 的治疗随着新型直接作用抗病毒药物的发展取得了重大进展。核苷酸聚合酶抑制剂是这些新药物中的一类，已被证明在抗病毒治疗方案中具有高度有效性、安全性和良好耐受性。索非布韦已成为该类药物中第一个获得临床批准的药物，其结果得到了广泛的 II 期和 III 期临床试验的支持。本文将进一步讨论核苷酸聚合酶抑制剂，包括支持其作为无干扰素 HCV 治疗方案一部分的使用数据。
